[Botulism: prevention, clinical diagnostics, therapy and possible threat].
In times of increased terrorist threat health professionals need to be prepared for bioterrorist events. The goal must be to give doctors an overview over the current state of knowledge and risk assessment of botulinum toxin. This review is based on Information gathered by a systematic analysis of the literature and by contacting experts. The toxicity of botulinum toxin exceeds any other known natural toxin. Clinical features of botulism consist of an acute, afebrile symmetrical and descending paralysis, regardless of the route of exposure, with normal mental status, sensory functions and electrolyte values. The initial diagnosis is often wrong in individual cases of botulism, but clusters with typical symptoms and two or more cases usually provide the diagnosis. Current treatment is primarily supportive care, respiratory support and antitoxin administration. Early application of antitoxin can limit the extent of the paralysis, but will not reverse it. Antitoxin for adult patients is of equine origin, while children in the USA can be treated with a recently developed human antitoxin. A pentavalent toxoid vaccine is available for persons at high risk of exposure. Botulinum toxin is easily extracted and ubiquitously available. These two features, together with the high toxicity, makes misuse easy. Misuse will continue to occur. Although a rare disease in Western Europe, botulism should be included in the differential diagnosis in patients with specific symptoms of paralysis. There is the potential threat of deliberate release of botulinum toxin. For this reason every outbreak of botulism must be assessed for any possible links to terrorism.
Gutzwiller
F S
FS
Abteilung für Ubertragbare Krankheiten und Zentrum für Reisemedizin, Universität Zürich/ISPM, Schweiz.
Steffen
R
R
Mathys
P
P
Walser
S
S
Schmid
H
H
Mütsch
M
M
D000328:Adult; D001905:Botulinum Toxins / Q000633:toxicity; D001906:Botulism / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy*; D003014:Clostridium botulinum; D005858:Germany / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D013557:Switzerland / Q000453:epidemiology
D001905:Botulinum Toxins